Comments
Shares of Cadila Healthcare gained as much as 1.5% in Friday's trade as Zydus Cadila has received final approval from the US health regulator to market minocycline hydrochloride extended release tablets used to treat acne.
The company has got final approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 45 mg, 80 mg, 90 mg, 105 mg and 135 mg, Zydus Cadila said in a BSE filing today.
Following a weak open at Rs 443.20 against the previous close of Rs 443.50, the scrip touched an intraday high of Rs 450.40 and a low of Rs 442.20. In terms of equity volume, 0.5 lakh shares were traded on the BSE.
The company shares ended up by 0.62 per cent at Rs 446.25.
Cadila Healthcare is the listed entity of the Zydus Group.
(With inputs from PTI)
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.